metformin has been researched along with Vasculitis in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Vasculitis: Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of metformin (1000 mg twice a day) on markers of endothelial activation, inflammation, and coagulation was investigated in subjects with impaired glucose tolerance (IGT) in a 16-wk, randomized, placebo-controlled, double-blind study." | 9.11 | The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. ( Aguilar-Salinas, CA; Caballero, AE; Cabrera, T; Castillo, JL; Delgado, A; Gomez-Perez, FJ; Herrera, AN; Rull, JA, 2004) |
| "The effect of metformin (1000 mg twice a day) on markers of endothelial activation, inflammation, and coagulation was investigated in subjects with impaired glucose tolerance (IGT) in a 16-wk, randomized, placebo-controlled, double-blind study." | 5.11 | The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. ( Aguilar-Salinas, CA; Caballero, AE; Cabrera, T; Castillo, JL; Delgado, A; Gomez-Perez, FJ; Herrera, AN; Rull, JA, 2004) |
| "In patients with type 2 diabetes mellitus (T2DM), biomarkers reflecting inflammation and endothelial dysfunction have been linked to cardiovascular disease (CVD biomarkers) and metabolic regulation." | 2.73 | Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. ( Frandsen, M; Gram, J; Lund, SS; Parving, HH; Pedersen, O; Schalkwijk, CG; Smidt, UM; Stehouwer, CD; Tarnow, L; Teerlink, T; Vaag, AA; Winther, K, 2008) |
| "Hyperglycemia and hyperlipidemia directly affected the contractile function of VSMCs." | 1.42 | Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway. ( Chen, XY; Lan, D; Li, T; Liu, LM; Tian, KL; Wu, Y; Yang, GM; Zhu, Y, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, T | 1 |
| Yang, GM | 1 |
| Zhu, Y | 1 |
| Wu, Y | 1 |
| Chen, XY | 1 |
| Lan, D | 1 |
| Tian, KL | 1 |
| Liu, LM | 1 |
| Caballero, AE | 1 |
| Delgado, A | 1 |
| Aguilar-Salinas, CA | 1 |
| Herrera, AN | 1 |
| Castillo, JL | 1 |
| Cabrera, T | 1 |
| Gomez-Perez, FJ | 1 |
| Rull, JA | 1 |
| Lund, SS | 1 |
| Tarnow, L | 1 |
| Stehouwer, CD | 1 |
| Schalkwijk, CG | 1 |
| Teerlink, T | 1 |
| Gram, J | 1 |
| Winther, K | 1 |
| Frandsen, M | 1 |
| Smidt, UM | 1 |
| Pedersen, O | 1 |
| Parving, HH | 1 |
| Vaag, AA | 1 |
2 trials available for metformin and Vasculitis
| Article | Year |
|---|---|
The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial.
Topics: Adult; Biomarkers; Blood Glucose; Cell Adhesion Molecules; Double-Blind Method; Endothelium, Vascula | 2004 |
Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Body Weight; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabeti | 2008 |
1 other study available for metformin and Vasculitis
| Article | Year |
|---|---|
Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Connexins; Diabetes Mellitu | 2015 |